Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.71

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $2.71, but opened at $2.65. Taysha Gene Therapies shares last traded at $2.72, with a volume of 69,852 shares traded.

Analyst Ratings Changes

TSHA has been the subject of several recent research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Chardan Capital increased their price objective on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Finally, Needham & Company LLC raised their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $6.57.

Taysha Gene Therapies Trading Down 1.5 %

The firm’s 50-day moving average price is $2.30 and its two-hundred day moving average price is $2.12. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of Taysha Gene Therapies by 2,035.0% during the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock worth $77,508,000 after purchasing an additional 23,378,974 shares during the period. RA Capital Management L.P. acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth approximately $58,373,000. RTW Investments LP acquired a new stake in shares of Taysha Gene Therapies during the third quarter worth approximately $53,382,000. Vanguard Group Inc. lifted its stake in Taysha Gene Therapies by 16.3% in the fourth quarter. Vanguard Group Inc. now owns 6,195,567 shares of the company’s stock valued at $10,966,000 after acquiring an additional 867,703 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its stake in Taysha Gene Therapies by 11.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after acquiring an additional 430,555 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.